NCCBF News Alert Ncc Ab B Free Shs (NCCBF) 30.9500 02/15/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ncc Ab B Free Shs (NCCBF) 30.9500 $NCCBF

NCC awarded SEK600m order to build two Choice hotels in Stockholm
M2 - Tue Feb 10, 4:49AM CST
NCC AB (STO:NCCA), a construction, property development and infrastructure company, announced on Monday that it has been commissioned by AMF Fastigheter to create, on a partnering basis, two new Choice hotels with a total of 540 rooms in existing properties by the Gallerian shopping mall in Stockholm.

NCC announces sale of office project with property value of SEK820m
M2 - Mon Feb 09, 6:39AM CST
NCC AB (STO:NCCB.ST) announced on Monday that it has sold an office project Lysaker Polaris in Oslo to Storebrand Eiendom AS.

NCC posts profit of SEK1,838m for year 2014
M2 - Tue Jan 27, 6:19AM CST
NCC AB (STO:NCCA), a construction, property development and infrastructure company in Northern Europe, on Tuesday reported profit after tax of SEK1,838m, or EPS of SEK17.01, for the year 2014, from 1 January 2014 to 31 December 2014.

NCC awarded SEK265m construction contract in Nordhavnen, Copenhagen
M2 - Fri Dec 19, 5:06AM CST
NCC AB (STO:NCCA), a construction, property development and infrastructure company in Northern Europe, announced on Thursday that it has been commissioned by the Marmorbyen limited partnership to build 133 rental units in Copenhagen's Nordhavnen district.

NCC announces sale of SEK268m worth of development rights and plans for new housing in Nacka, Stockholm
M2 - Wed Dec 17, 6:43AM CST
NCC AB (STO:NCCA), a construction, property development and infrastructure company, announced on Tuesday the sale of development rights valued at SEK268m to property company HSB Bostad for the development of about 220 housing units in the Tollare area of Nacka Municipality, Stockholm.

NCC divests land valued at SEK195m
M2 - Mon Dec 15, 6:23AM CST
NCC AB (STO:NCCB.ST) , a construction, property development and infrastructure company, announced on Friday the sale of development rights with a value of SEK195m to Jarntorget Bostad AB for the development of about 300 housing units in the Ursvik area in the city of Sundbyberg, Stockholm.

Construction in Sweden - Key Trends and Opportunities to 2018
M2 - Wed Jul 09, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/crh4kr/construction_in) has announced the addition of the "Construction in Sweden - Key Trends and Opportunities to 2018" report to their offering. The Swedish construction industry posted a compound annual growth rate (CAGR) of 4.21% during the review period (2009-2013), supported by private and public investments in infrastructural, residential, industrial and commercial construction projects. Despite the challenging environment, the outlook for the country's construction industry is favorable due to the government's commitment to improving the country's infrastructure, meeting rising demand for residential units. Consequently, the construction industry's output is expected to record a CAGR of 4.80% over the forecast period. This report provides a comprehensive analysis of the construction industry in Sweden. It provides: - Historical (2009-2013) and forecast (2014-2018) valuations of the construction industry in Sweden using construction output and value-add methods - Segmentation by sector (commercial, industrial, infrastructure, institutional and residential) and by project type - Breakdown of values within each project type, by type of activity (new construction, repair and maintenance, refurbishment and demolition) and by type of cost (materials, equipment and services) - Analysis of key construction industry issues, including regulation, cost management, funding and pricing - Detailed profiles of the leading construction companies in Sweden Reasons To Buy - Identify and evaluate market opportunities using our standardized valuation and forecasting methodologies - Assess market growth potential at a micro-level with over 600 time-series data forecasts - Understand the latest industry and market trends - Formulate and validate business strategies using Timetric's critical and actionable insight - Assess business risks, including cost, regulatory and competitive pressures - Evaluate competitive risk and success factors Key Topics Covered: 1 Executive Summary 2 Market Overview 3 Commercial Construction 4 Industrial Construction 5 Infrastructure Construction 6 Institutional Construction 7 Residential Construction 8 Company Profile: Peab AB 9 Company Profile: JM AB 10 Company Profile: Skanska AB 11 Company Profile: NCC AB 12 Company Profile: NCC Property Development AB 13 Market Data Analysis 14 Appendix Companies Mentioned: - Peab - JM - Skanska - NCC - NCC Property Development For more information visit http://www.researchandmarkets.com/research/cr...ruction_in




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading